Strides Pharma Science (NSE:STAR) Moat Score: 0/10 (As of Jun. 30, 2026)


NSE:STAR Strides Pharma Science Ltd NSE:STAR
68 GF Score
Price ₹1,103.40
GF Value ₹773.22
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Strides Pharma Science Moat Score?

Strides Pharma Science has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Strides Pharma Science has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Strides Pharma Science might have No Moat - No discernible moat.

Strides Pharma Science  (NSE:STAR) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Strides Pharma Science Moat Score Related Terms

NSE:STAR
68GF Score
Strides Pharma Science Ltd NSE:STAR
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Strides Pharma Science (NSE:STAR) Overvalued in 2026?

Based on GuruFocus' analysis, Strides Pharma Science stock appears to be overvalued. The current stock price of ₹1,103.40 is trading 42.7% above its estimated GF Value™ of ₹773.22. GuruFocus considers Strides Pharma Science to be Significantly Overvalued.

Key valuation signals for NSE:STAR:

  • Moat Score: 0
  • GF Value™: ₹773.22 vs. price of ₹1,103.40 (42.7% above fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the NSE:STAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Strides Pharma Science Business Description

Other Exchanges 532531:India
Address Bannerghatta Road, Strides House, Bilekahalli, Bengaluru, KA, IND, 560076
Strides Pharma Science Ltd develops and manufactures a wide range of IP-led niche pharmaceutical products. Its diverse portfolio spans complex generics across multiple dosage forms, including tablets, hard capsules, sachets, liquids, nasal sprays, topicals, and controlled substances. It also manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for its institutional business. The customers for this business include institutionally funded aid projects and procurement agencies. With its R&D, integration, and distribution network, the company brings differentiated products to market across the U.S., Australia, Europe, Africa, and Emerging Markets. Geographically, it generates maximum revenue from North America.
68GF Score

Get the complete analysis for NSE:STAR

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,103.40
Price
₹773.22
GF Value